0.91
-1.51%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ExpreS2ion Biotech Holding
Its shares trade on Nasdaq Stockholm under the ticker EXPRS2.ST. It has been listed since 29 July 2016. In the fiscal year to 31 December 2025, it reported revenue of SEK 3.7m and a net loss of SEK 38.1m. At that date it held total assets of SEK 65.1m and shareholders' equity of SEK 35.7m.
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Jul 2016
- Employees
- 28
Leadership
Pay as last reported
- Dr. Martin JensenChairman of the Board
- Mr. Bent FrandsenChief Executive Officer, since 2019
- Mr. Keith AlexanderChief Financial Officer
- Ms. Mette ThornVice President - Preclinical Development
- Mr. Max SogaardVice President - Research & Development and Technology
- Mr. Mattis RantheChief Medical Officer
- Dr. Allan RosetzskyBoard Member
- Ms. Karin GarreIndependent Member of the Board
- Mr. Jakob KnudsenIndependent Member of the Board
- Ms. Sara SandeIndependent Member of the Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ExpreS2ion Biotech Holding AB develops vaccines for COVID-19, influenza, and breast cancer.
- The ExpreS2 platform supports all phases of drug development and manufacturing.
- AdaptVac ApS applies Plug-and-Play Virus Like Particle technology for vaccines.
Weaknesses
- The company employs only 28 full-time employees.
- Helsingborg, Skane is the headquarters city for the company.
- The company went public on 29 July 2016.
Opportunities
- The company's focus on oncology and infectious diseases offers growth potential.
- The ExpreS2 platform can be used for transient or stable transfections.
- The joint venture AdaptVac ApS expands vaccine development capabilities.
Threats
- The biotechnology sector faces intense competition for vaccine development.
- The company must address high cell density challenges without aggregation.
- Regulatory hurdles may impact vaccine approval timelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.